Luteolin relieves lung cancer-induced bone pain by inhibiting NLRP3 inflammasomes and glial activation in the spinal dorsal horn in mice

• DOI: 10.1016/j.phymed.2021.153910
• Publication Date: 2021-12-25T06:42:20Z
• Authors: Yong-Sheng Zhou; Yue Cui; Jia-Xin Zheng; Ya-Qi Quan; Sheng-Xi Wu; Hui Xu; Yong Han
• Keywords: 0301 basic medicine; Spinal Cord Dorsal Horn; Lung Neoplasms; Inflammasomes; Pain; NLR Proteins; Rats; 3. Good health; Rats, Sprague-Dawley; Mice; 03 medical and health sciences; NLR Family, Pyrin Domain-Containing 3 Protein; Neuroinflammatory Diseases; Animals; Humans; Luteolin

Bone cancer pain (BCP) is one of the most severe complications in cancer patients. However, the pharmacological therapeutic approaches are limited. Luteolin, a major component of flavones, is widely distributed in plants and plays a critical role in the antinociceptive effects, but whether luteolin could alleviate cancer pain and its underlying mechanisms are not known.This study investigated the molecular mechanisms by which luteolin reduced BCP.Behavioral, pharmacological, immunohistochemical, and biochemical approaches were used to investigate the effect of luteolin on BCP.Luteolin treatment ameliorated Lewis lung cancer (LLC)-induced bone pain in mice in a dose-dependent manner. Luteolin treatment could inhibit the activation of neurons, glial cells, and NOD-like receptor protein 3 (NLRP3) inflammasomes in the dorsal spinal cord in the BCP mouse model. Furthermore, phosphorylated p-38 mitogen-activated protein kinase (MAPK) in the spinal dorsal horn (SDH) was suppressed by luteolin treatment that could influence the analgesic and glial inhibition effects of luteolin.Our results demonstrated that luteolin inhibited neuroinflammation by obstructing glial cell and NLRP3 inflammasome activation via modulating p38 MAPK activity in SDH, ultimately improving LLC-induced BCP.